D-lysine for reduction of renal [In-111-DTPA,D-Phe-1]-octreotide and [Y-90-DOTA,D-Phe-1,Tyr-3]octreotide uptake

被引：0
|
作者：
deJong, M
Bernard, B
Breeman, W
Bakker, W
Visser, T
Macke, H
Krenning, E
机构：
[1] UNIV HOSP DIJKZIGT,DEPT NUCL MED,NL-3015 GD ROTTERDAM,NETHERLANDS
[2] KANTONSSPITAL,DEPT NUCL MED,CH-4031 BASEL,SWITZERLAND
来源：
EUROPEAN JOURNAL OF CANCER | 1997年 / 33卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：52 / 52
页数：1
相关论文
共 50 条
  • [1] D-lysine for reduction of renal [In-111-DTPA,D-Phe-1]octreotide and [Y-90-DOTA,D-Phe-1,Tyr-3]octreotide uptake.
    Bernard, B
    Krenning, E
    Rolleman, E
    Breeman, W
    Bakker, W
    Visser, T
    Macke, H
    deJong, M
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 817 - 817
  • [2] Receptor binding and biodistribution of Y-90- and In-111-[DOTA,D-Phe-1,Tyr-3]octreotide, promising for radionuclide therapy.
    deJong, M
    Bakker, W
    Krenning, E
    Breeman, W
    vanderPluijm, M
    Bernard, B
    Visser, T
    Jermann, E
    Behe, M
    Powell, P
    Macke, HR
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 1061 - 1061
  • [3] Biodistribution of a new chelated somatostatin analogue, [In-111-DOTA-D-Phe-1-Tyr-3]-octreotide; Comparison with [In-111-DTPA-D-Phe-1]-octreotide in humans.
    Krenning, EP
    Bakker, WH
    Kwekkeboom, DJ
    Kooi, PPM
    vanderPluijm, ME
    Behe, M
    Macke, H
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (05) : 382 - 382
  • [4] 111In-DTPA-D-Phe-1-Asp0-D-Phe1-octreotide exhibits higher tumor accumulation and lower renal radioactivity than 111In-DTPA-D-Phe1-octreotide
    Oshima, Nobuhiro
    Akizawa, Hiromichi
    Kitaura, Hirotake
    Kawashima, Hidekazu
    Zhao, Songji
    Zhao, Yan
    Nishijima, Ken-ichi
    Kitamura, Yoji
    Arano, Yasushi
    Kuge, Yuji
    Ohkura, Kazue
    NUCLEAR MEDICINE AND BIOLOGY, 2017, 54 : 18 - 26
  • [5] Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
    Giovanni Paganelli
    Stefania Zoboli
    Marta Cremonesi
    Lisa Bodei
    Mahila Ferrari
    Chiara Grana
    Mirco Bartolomei
    Franco Orsi
    Concetta De Cicco
    Helmut R. Mäcke
    Marco Chinol
    Filippo de Braud
    European Journal of Nuclear Medicine, 2001, 28 : 426 - 434
  • [6] Receptor-mediated radiotherapy with 90Y-DOTA-D-Phe1-Tyr3-octreotide
    Paganelli, G
    Zoboli, S
    Cremonesi, M
    Bodei, L
    Ferrari, M
    Grana, C
    Bartolomei, M
    Orsi, F
    De Cicco, C
    Mäacke, HR
    Chinol, M
    de Braud, F
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 2001, 28 (04) : 426 - 434
  • [7] Renal metabolism of 111In-DTPA-D-Phe1-octreotide in vivo
    Akizawa, H
    Arano, Y
    Uezono, T
    Ono, M
    Fujioka, Y
    Uehara, T
    Yokoyama, A
    Akaji, K
    Kiso, Y
    Koizumi, M
    Saji, H
    BIOCONJUGATE CHEMISTRY, 1998, 9 (06) : 662 - 670
  • [8] D-lysine reduction of indium-111 octreotide and yttrium-90 octreotide renal uptake
    Bernard, BF
    Krenning, EP
    Breeman, WAP
    Rolleman, EJ
    Bakker, WH
    Visser, TJ
    Mäcke, H
    de Jong, M
    JOURNAL OF NUCLEAR MEDICINE, 1997, 38 (12) : 1929 - 1933
  • [9] Therapy using labelled somatostatin analogues:: comparison of the absorbed doses with 111In-DTPA-D-Phe1-octreotide and yttrium-labelled DOTA-D-Phe1-Tyr3-octreotide
    Barone, Raffaella
    Walrand, Stephan
    Konijnenberg, Mark
    Valkema, Roelf
    Kvols, Larry K.
    Krenning, Eric R.
    Pauwels, Stanislas
    Jamar, Francois
    NUCLEAR MEDICINE COMMUNICATIONS, 2008, 29 (03) : 283 - 290
  • [10] Distribution and elimination characteristics of111In-DTPA-D-Phe1-octreotide and111In-DTPA-L-Phe1-octreotide in rats
    Alice Laznickova
    M. Laznicek
    F. Trejtnar
    L. Melicharova
    Kazuko Horuichi Suzuki
    Hiromichi Akizawa
    Yasushi Arano
    Akira Yokoyama
    European Journal of Drug Metabolism and Pharmacokinetics, 2002, 27 : 37 - 43
12345